News

A meta-analysis by IDIBELL and Bellvitge Hospital examines the use of beta-lactam antibiotics in febrile neutropenia

The results of five studies have been reviewed, two of them randomized clinical trials, with a total of 691 episodes of febrile neutropenia. The effects of the use of beta-lactam antibiotics in intermittent infusions have been compared with prolonged infusions.

Leer más about A meta-analysis by IDIBELL and Bellvitge Hospital examines the use of beta-lactam antibiotics in febrile neutropenia

New research will look for risk indicators of harmful internet use among adolescents

Dr. Josep Manuel Menchon, group leader at IDIBELL and head of the Psychiatry Service at Bellvitge University Hospital, participates in a pioneering study led by the University of Hertfordshire to address and reduce the risks of harmful Internet use among adolescents.

Leer más about New research will look for risk indicators of harmful internet use among adolescents

Maria Eulàlia Juvé and Jordi Adamuz participate in the publication of a nursing mentoring book

The article by Juvé and Adamuz highlights the importance of knowledge of nursing tools and strategies (ATIC and ARES) to improve patient outcomes and the work environment.

Leer más about Maria Eulàlia Juvé and Jordi Adamuz participate in the publication of a nursing mentoring book

The IDIBELL educational Tandem with the Institut Bellvitge closes the 2022-23 academic year with the launch of new activities

The participation of Institute students in the IDIBELL sLHam for women scientists, the creation of a new Sant Jordi award or the co-creation of content and activities for the new Biomedicine subject have been the main novelties of the course.

Leer más about The IDIBELL educational Tandem with the Institut Bellvitge closes the 2022-23 academic year with the launch of new activities

A new neuroprotective drug shows good preliminary results for ischemic stroke

According to the results of the APRIL study, in which the Hospital de Bellvitge and IDIBELL have participated, ApTOLL has shown good safety in 151 patients with acute ischemic stroke.

Leer más about A new neuroprotective drug shows good preliminary results for ischemic stroke

Another year at IDIBELL we maintain our commitment to research, training and innovation to improve people’s health

In 2022, with almost 1,500 published articles, of which almost 600 were led by IDIBELL researchers, our research maintained its high level of quality and excellence, with an average impact factor greater than nine.

Leer más about Another year at IDIBELL we maintain our commitment to research, training and innovation to improve people’s health

A study postulates vaginal self-sample and urine as applicable tools for endometrial cancer diagnosis and prognosis

Two studies led by IDIBELL and the Catalan Institute of Oncology show that DNA sequencing in these samples can detect endometrial cancer, which would avoid much more invasive and painful methods.

Leer más about A study postulates vaginal self-sample and urine as applicable tools for endometrial cancer diagnosis and prognosis

IDIBELL and CIBER researchers identify a new genetic disease that affects the development of the nervous system and causes liver failure

RINT1 mutations would be causing a deregulation of fat metabolism and intracellular communication of energy production. This is a significant advance in the understanding of this disease, and opens new perspectives for diagnosis and possible treatment in the future.

Leer más about IDIBELL and CIBER researchers identify a new genetic disease that affects the development of the nervous system and causes liver failure

New collaboration with Blue Zone Studio to create an OCD monitoring application

The application will monitor in real-time and, combined with neuroimaging studies, will allow the identification of new biomarkers to predict the disease evolution.

Leer más about New collaboration with Blue Zone Studio to create an OCD monitoring application
Scroll to Top